Atrioventricular Block in the Setting of Immune Myocarditis: A Pragmatic Approach to Diagnosis and Treatment
- 16 November 2024
- journal article
- review article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (12) , 1617-1626
Abstract
Immunotherapy has revolutionized cancer treatment in the last decade and has significantly improved patient survival. However, immunotherapy is associated with serious cardiac adverse events including myocarditis and conduction disturbances. In the literature, the mortality rate in patients with immunotherapy‐associated myocarditis and complete AV block is reported to be approximately 60%. Current cardio‐oncology guidelines provide a series of recommendations for the management of immune myocarditis (IM). However, there is no recommendation on whether or when pacemaker implantation should be performed in the setting of complete AV block associated with myocarditis. This gap in the literature has led to a trend in cardio‐oncology practice to implant permanent pacemakers (PPMs) in a significant proportion of patients without waiting for a response to immunosuppressive therapy. However, in a significant proportion of patients undergoing PPM implantation, complete AV block resolves after immunosuppressive therapy. This suggests that in cases of complete AV block in the setting of IM, more robust clues are needed for PPM implantation. This review aims to present algorithms for the management of myocarditis and complete AV block, one of the most lethal complications of immunotherapy, to help fill this gap in the literature.Keywords
This publication has 62 references indexed in Scilit:
- Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case ReportThe American Journal of Cardiology, 2023
- Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditisArchives of Cardiovascular Diseases, 2022
- Beyond the wrist: Using a smartwatch electrocardiogram to detect electrocardiographic abnormalitiesArchives of Cardiovascular Diseases, 2022
- Wearable Cardioverter-Defibrillator: Friend or Foe in Suspected Myocarditis?ESC Heart Failure, 2021
- Benefit of a Wearable Cardioverter Defibrillator for Detection and Therapy of Arrhythmias in Patients with MyocarditisESC Heart Failure, 2021
- Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and StrategiesCurrent Cardiology Reports, 2021
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor DrugsJAMA Network Open, 2020
- Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported casesJournal of Cancer Research and Clinical Oncology, 2019
- Use of the Wearable Cardioverter Defibrillator in High-Risk PopulationsCurrent Cardiology Reports, 2016
- Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacingThe American Journal of Cardiology, 1982